Stock NRBO NEUROBO PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News NeuroBo Pharmaceuticals, Inc.

Equities

NRBO

US64132R4048

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
3.81 USD -6.16% Intraday chart for NeuroBo Pharmaceuticals, Inc. -7.75% +3.07%
May. 22 NeuroBo Pharmaceuticals, Inc. Announces Pre-Clinical Data of DA-1241, a Novel G-Protein-Coupled Receptor 119 Agonist, in Combination with Semaglutide CI
May. 09 NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NeuroBo Pharmaceuticals, Inc. Announces Pre-Clinical Data of DA-1241, a Novel G-Protein-Coupled Receptor 119 Agonist, in Combination with Semaglutide
CI
NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone
PR
NeuroBo Pharmaceuticals : Company Presentation May 2024
PU
NeuroBo Pharmaceuticals : Company Presentation May 2024
PU
NEUROBO PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
AQ
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target
MT
NEUROBO TO PRESENT LATEST PRE-CLINICAL DATA ON CARDIOMETABOLIC ASSETS, DA-1241 AND DA-1726, TARGETING MASH AND OBESITY, AT SCIENTIFIC CONFERENCES IN JUNE
AQ
Sector Update: Health Care Stocks Mixed Wednesday Afternoon
MT
NeuroBo Begins Dosing in Phase 1 Study of Obesity Treatment; Shares Rise
MT
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
PR
NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity
CI
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
PR
NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash
CI
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
PR
NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
NeuroBo Pharmaceuticals to Continue Trial of Liver Disease Treatment Candidate -- Shares Down
MT
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
PR
NeuroBo Pharmaceuticals, Inc. Receives Safety Review Committee Approval to Continue with Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash
CI
NeuroBo Pharmaceuticals Names Marshall Woodworth Finance Chief
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NRBO Stock
  4. News NeuroBo Pharmaceuticals, Inc.